176 related articles for article (PubMed ID: 11276033)
1. Optimal two-stage designs for clinical trials based on safety and efficacy.
Thall PF; Cheng SC
Stat Med; 2001 Apr; 20(7):1023-32. PubMed ID: 11276033
[TBL] [Abstract][Full Text] [Related]
2. Alternative designs of phase II trials considering response and toxicity.
Jin H
Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
[TBL] [Abstract][Full Text] [Related]
3. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
4. A three-outcome design for randomized comparative phase II clinical trials.
Hong S; Wang Y
Stat Med; 2007 Aug; 26(19):3525-34. PubMed ID: 17262879
[TBL] [Abstract][Full Text] [Related]
5. Two-stage designs for phase II cancer trials with ordinal responses.
Stallard N; Cockey L
Contemp Clin Trials; 2008 Nov; 29(6):896-904. PubMed ID: 18703164
[TBL] [Abstract][Full Text] [Related]
6. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
Masaki N; Koyama T; Yoshimura I; Hamada C
J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
[TBL] [Abstract][Full Text] [Related]
7. Admissible two-stage designs for phase II cancer clinical trials.
Jung SH; Lee T; Kim K; George SL
Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
[TBL] [Abstract][Full Text] [Related]
8. A parallel phase I/II clinical trial design for combination therapies.
Huang X; Biswas S; Oki Y; Issa JP; Berry DA
Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
[TBL] [Abstract][Full Text] [Related]
9. Toxicity-evaluation designs for phase I/II cancer immunotherapy trials.
Messer K; Natarajan L; Ball ED; Lane TA
Stat Med; 2010 Mar; 29(7-8):712-20. PubMed ID: 20213706
[TBL] [Abstract][Full Text] [Related]
10. Construction of group sequential designs in clinical trials on the basis of detectable treatment differences.
Schäfer H; Müller HH
Stat Med; 2004 May; 23(9):1413-24. PubMed ID: 15116350
[TBL] [Abstract][Full Text] [Related]
11. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
Johnson VE; Cook JD
Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
[TBL] [Abstract][Full Text] [Related]
12. Optimal conditional error functions for the control of conditional power.
Brannath W; Bauer P
Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
[TBL] [Abstract][Full Text] [Related]
13. A group-sequential design for clinical trials with treatment selection.
Stallard N; Friede T
Stat Med; 2008 Dec; 27(29):6209-27. PubMed ID: 18792085
[TBL] [Abstract][Full Text] [Related]
14. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.
Thall PF; Russell KE
Biometrics; 1998 Mar; 54(1):251-64. PubMed ID: 9544520
[TBL] [Abstract][Full Text] [Related]
15. Adaptive two-stage designs in phase II clinical trials.
Banerjee A; Tsiatis AA
Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
[TBL] [Abstract][Full Text] [Related]
16. Efficient group sequential designs when there are several effect sizes under consideration.
Jennison C; Turnbull BW
Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
[TBL] [Abstract][Full Text] [Related]
17. Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer.
Royston P; Parmar MK; Qian W
Stat Med; 2003 Jul; 22(14):2239-56. PubMed ID: 12854091
[TBL] [Abstract][Full Text] [Related]
18. Analysing sequential events in clinical trials.
Salter A; Raab G; Day S
Clin Trials; 2006; 3(5):421-30. PubMed ID: 17060216
[TBL] [Abstract][Full Text] [Related]
19. Designs for phase II trials allowing for a trade-off between response and toxicity.
Conaway MR; Petroni GR
Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
[TBL] [Abstract][Full Text] [Related]
20. Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data.
Heller G; Kattan MW; Scher HI
Med Decis Making; 2007; 27(4):380-6. PubMed ID: 17761958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]